Madrigal Pharmaceuticals logo

Manager, Biostatistics

Madrigal Pharmaceuticals

Conshohocken, PAOnsitePosted 16 days ago$148,760 - $181,276 per year
Full TimeMid LevelBioinformatics & Data SciencePharmaceutical
Original posting ↗

Summary

The Manager, Biostatistics is an early-career individual contributor that will contribute to multiple biostatistical activities for Madrigal Pharmaceuticals, covering all phases of clinical development and post-marketing efforts. This role will support the translation of organizational objectives into statistical deliverables, contribute to the execution of statistical strategies, and deliver high-quality analytical outputs. This role will collaborate with other biostatisticians, programmers and cross-functional team members either within the company or at a CRO partner to ensure that Madrigal's analytical objectives are met. This role provides hands-on biostatistics experience in clinical development and post-marketing evidence generation, while building expertise under senior statistical guidance. This position reports into the Senior Director of Biostatistics.

Job description

Responsibilities

  • Execute statistical modeling and analyses, coordinating with other biostatisticians, programmers and cross-functional team members to meet R&D objectives.
  • Perform and review complex statistical analyses, contribute to protocol development and prepare Statistical Analysis Plans as needed.
  • Contribute to the design of clinical and real-world studies and perform analyses of clinical and real-world data to support evidence generation initiatives from randomized trials as well as observational studies.
  • Establish effective collaborations with cross-functional team members, such as clinical research, medical affairs, clinical operations and data management.
  • Contribute to scientific excellence via statistical innovation and participation in external conferences.

Qualifications

  • Ph.D. in (Bio)statistics with 0-3 years, or a Master's degree with 5+ years of experience in a Pharma or Biotech environment.
  • Experience in design and analysis of clinical trials and healthcare datasets.
  • Solid foundation in advanced statistical methods and computing (R, SAS).
  • Effectively communicates complex statistical analyses and concepts to non-statisticians.
  • Knowledge of regulatory guidelines in pharmaceutical development is a plus.
  • Excellent organizational and communication skills.

Requirements

  • Ph.D. in (Bio)statistics with 0-3 years, or a Master's degree with 5+ years of experience in a Pharma or Biotech environment.
  • Experience in design and analysis of clinical trials and healthcare datasets.
  • Solid foundation in advanced statistical methods and computing (R, SAS).
  • Effectively communicates complex statistical analyses and concepts to non-statisticians.
  • Knowledge of regulatory guidelines in pharmaceutical development is a plus.
  • Excellent organizational and communication skills.

Benefits

  • Flexible paid time off
  • Medical, dental & vision insurance
  • Life & disability insurance
  • 401(k) with employer match
  • Equity
  • Mental health benefits
  • Employee Assistance Program
  • Supplemental life insurance
  • Legal services

Company overview

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. The company's lead product, Rezdiffra (resmetirom), is a once-daily, oral thyroid hormone receptor (THR)-β selective agonist that targets key underlying causes of MASH in the liver. Rezdiffra received FDA approval in 2024 as the first treatment for MASH with moderate to advanced liver fibrosis, representing a significant breakthrough in hepatology. Headquartered in Conshohocken, Pennsylvania, Madrigal is publicly traded on NASDAQ under the symbol MDGL. The company continues to advance its clinical development programs, including ongoing Phase 3 trials evaluating Rezdiffra for the treatment of compensated MASH cirrhosis. Madrigal's innovative approach addresses a critical unmet medical need in liver disease therapeutics.

Explore more jobs of your matchFind more biopharma roles with GetBioJob.